RecruitingNot ApplicableNCT06836284

The Evira Study: Additional Support During Obesity Treatment

Evaluation of a Digital Treatment Tool in Combination With Obesity Medications


Sponsor

Karolinska Institutet

Enrollment

40 participants

Start Date

Feb 13, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is: \- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone? This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.


Eligibility

Min Age: 12 YearsMax Age: 17 Years

Inclusion Criteria3

  • Patients offered liraglutide or semaglutide in accordance with the clinic's routines.
  • Aged 12-17 years at the time of inclusion.
  • The family agrees to participate in a clinical study.

Exclusion Criteria6

  • Endocrine disorders other than well-controlled hypothyroidism.
  • Severe neuropsychiatric disorders that may affect adherence to the study.
  • Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion.
  • Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment.
  • Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome.
  • Patients deemed unsuitable for participation by the responsible physician.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDigi-physical treatment tool, Evira

A digi-physical treatment tool named Evira will be used to provide behavioral treatment.

DRUGObesity medication with liraglutide or semaglutide

Obesity medication with liraglutide or semaglutide according to the clinic's standard procedure


Locations(2)

HKH Crown Princess Victoria's Childrens and youth Hospital Linköping

Linköping, Sweden

Ystad lasarett, Barn och ungdomsmedicinmottagningen

Ystad, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06836284


Related Trials